The Survey of Serum sTNFR1 Level in Conversion Process from Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)

The activation of inflammatory cascades reactions has been consistently demonstrated in the pathophysiology of Alzheimer’s disease (AD). Among several neuroinflammatory mechanisms, the tumor necrosis factor (TNF) signaling system has a central role in this process. The abnormal production of inflammatory factors may accompany the progression from mild cognitive impairment (MCI) to dementia. We aimed to examine serum levels of soluble TNF receptor (sTNFR1) in patients with MCI and AD as compared to cognitively unimpaired elderly subjects. We further aimed to investigate whether abnormal levels of these cytokines predict the progression from MCI to AD upon follow up.
We utilized cross-sectional determination of serum levels of sTNFR1 (ELISA method) in a test group comprising 150 older adults (30 AD, 60 MCI, and 60 healthy controls), and longitudinal reassessment of clinical status after12 months.
At baseline, there were statistically significant differences in serum sTNFR1 between patients with MCI and AD and controls (p The results showed that abnormal activation of TNF signaling system, represented by increased expression of sTNFR1, is associated with a higher risk of progression from MCI to AD.